Real-World Outpatient Prescription Patterns for Atopic Dermatitis in the United States

Singh, Partik; Silverberg, Jonathan I.

doi:10.1097/der.0000000000000520

Cited by 16 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, topical CSs were the most commonly prescribed medications, both at the initiation of treatment and during the entire observation period in all age groups. This is in line with the results of previous studies that analyzed treatment patterns among children and adults with AD in the United States 11 . Not surprisingly, relevant guidelines also suggest topical CSs as the first-line treatment and maintenance therapy 12 , 13 .…”

Section: Discussionsupporting

confidence: 92%

Real-world treatment patterns for atopic dermatitis in South Korea

Lee

Choi

Noh

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The phenotypes of atopic dermatitis (AD) are diverse, and ethnic differences have been suggested. To date, few studies have explored large-scale national data on the treatment patterns of AD in Asians. Therefore, we aimed to examine real-world treatment patterns for AD, including the probability of discontinuation of AD treatment and restart after discontinuation. A retrospective observational study was conducted using the nationwide healthcare database in South Korea between January 1, 2016 to July 31, 2020. We identified 944,559 pediatric patients and 1,066,453 adults with AD. Topical corticosteroids and antihistamines were the most commonly prescribed medications in all age groups. The frequency of topical corticosteroid prescription decreased as the age increased. Although immunosuppressive drugs were not widely used in both children and adults, cyclosporine was the most frequently prescribed immunosuppressant, particularly among those aged 12 years or more (1–2%). Pediatric patients were more likely to discontinue treatment than adult patients. Treatment restart for moderate-to-severe AD was earlier than that for overall AD. In conclusion, significant differences were observed in the treatment patterns of AD between pediatric and adult patients. These findings will improve our understanding of the latest treatment patterns for AD, which may contribute to decision-making in clinical practice.

show abstract

Section: Discussionsupporting

confidence: 92%

Real-world treatment patterns for atopic dermatitis in South Korea

Lee

Choi

Noh

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…These features likely contribute to polypharmacy, complicated treatment regimens, and alternative treatments among patients with AD. 32 Our data demonstrate considerable prescription polypharmacy among AD patients, especially for those with increased severity, poorer control, increased HCP visits, and private or Medicare insurance. Many respondents reported OOP expenses for prescription medications regardless of insurance coverage.…”

Section: Discussionmentioning

confidence: 62%

Financial Burden of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the United States

et al. 2020

View full text Add to dashboard Cite

Background: Atopic dermatitis (AD) is associated with considerable financial cost. However, the full burden of out-ofpocket (OOP) expenses is not well understood.Objective: We sought to characterize the OOP health care expenses associated with AD management. Methods: A 25-question voluntary online survey was administered to National Eczema Association members worldwide (n = 113,502). Inclusion criteria (US residents age ≥18 years who either self-reported had AD or were primary caregivers of individuals with AD) were met by 77.3% (1118/1447) of respondents. Results: Respondents reported OOP expenses in 3 categories: (1) health care providers and prescriptions, including health care provider visit deductibles (68.7% [686]), prescription co-pays (64.3% [635]), and prescriptions not covered by insurance (48.6% [468]); (2) nonprescription health care products, including moisturizers (94.3% [934]), hygiene products (85.0% [824], allergy medications (75.1% [715]), itch relievers (68.25% [647]), dietary supplements (52.2% [491]), and sleep aids (37.0% [336]); and (3) complementary approaches, including cleaning products (74.7% [732]), clothing/bedding (44.8% [430]), alternative medications (19.0% [180]), and adjunctive therapies (15.

show abstract

“…This study provided a unique opportunity to combine routinely collected registry data with survey data including information regarding clinical characteristics and demographics of AD, and strongly expands knowledge from previous studies. 25,26 However, several limitations apply to the interpretation of these data. This was a cross-sectional study, and use of therapies and disease severity may fluctuate over time.…”

Section: Strengths and Limitationsmentioning

confidence: 99%

Treatment of adult atopic dermatitis patients according to disease characteristics and demographics

Thyssen

Andersen

Vittrup

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Little is currently known about possible associations between disease specific characteristics of atopic dermatitis (AD) and use of medical treatments. We explored the use of AD treatments within the past 12 months in Danish adults according to distinct patient characteristics. Patients who had received a diagnosis of AD in a hospital in-or outpatient setting as adults were surveyed and data cross-linked to a national prescription registry. AD severity was measured by the Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD). A total of 3834 patients participated. Use of topical medication in the past 12 months increased with increasing AD severity, whereas no difference was observed for systemic medication use. Positive associations between AD in the face and neck, and use of mild and moderately potent topical corticosteroids were observed, while involvement of palms and chest was associated with use of more potent topical corticosteroids. The mean DLQI, skin pain, and itch severity scores were lower in patients managed only with topical corticosteroids (5.5, 3.2, and 4.3, respectively) compared to patients treated with both oral and topical medication (7.1, 3.8, and 5.0, respectively). Patients with frequent topical corticosteroid use tended to be older (50.7 vs 48.6 years), males (50.0% vs 33.6%), current daily smokers (17.3% vs 13.7%), and having asthma (59.1% vs 43.8%) compared with infrequent users of topical corticosteroids. We found a disconnect between the severity of AD signs and symptoms, and use of AD therapies. In particular, a very modest use of systemic immunosuppressants was seen even among patients with severe AD symptoms. However, the underlying clinical decisions and reasons behind this disconnect is not clear based on the current data.

show abstract

Real-World Outpatient Prescription Patterns for Atopic Dermatitis in the United States

Cited by 16 publications

References 20 publications

Real-world treatment patterns for atopic dermatitis in South Korea

Real-world treatment patterns for atopic dermatitis in South Korea

Financial Burden of Atopic Dermatitis Out-of-Pocket Health Care Expenses in the United States

Treatment of adult atopic dermatitis patients according to disease characteristics and demographics

Contact Info

Product

Resources

About